The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced NSCLC.
 
Sheena Bhalla
No Relationships to Disclose
 
Farjana J. Fattah
No Relationships to Disclose
 
Jessica N. Williams
No Relationships to Disclose
 
Alyssa Macchiaroli
Employment - Flatiron Health
 
Jonathan Padro
No Relationships to Disclose
 
Meredith Pogue
No Relationships to Disclose
 
Jonathan Dowell
Consulting or Advisory Role - AstraZeneca; AstraZeneca/MedImmune; Genentech; Mirati Therapeutics
Research Funding - Novartis (Inst); Novocure; Pfizer (Inst); Trizell (Inst)
 
Rolf A. Brekken
Stock and Other Ownership Interests - Abbott; Abbvie; Regeneron
Consulting or Advisory Role - Vigeo Therapeutics
Research Funding - BerGenBio; iBio; Kura Oncology; Lilly; OncXerna Therapeutics; Tolero Pharmaceuticals
 
William C. Putnam
Employment - FAST BioMedical; Pfizer (I)
Leadership - FAST BioMedical
Stock and Other Ownership Interests - FAST BioMedical; Inceptor Bio; Pfizer (I)
Consulting or Advisory Role - CereMark Pharma; Inceptor Bio; ProPhos Neurosciences, LLC; Rarestone Pharmaceuticals
 
Nigel William McCracken
Employment - BerGenBio
 
David Micklem
Employment - BerGenBio
Stock and Other Ownership Interests - agenus; Arbutus Biopharma Corp; BerGenBio; Exelixis; Incyte; Merck; Regeneron
Research Funding - BerGenBio (Inst)
Patents, Royalties, Other Intellectual Property - Named inventor on several BerGenBio ASA patent applications (and granted patents).
 
Zenobia D'Costa
Employment - BerGenBio; GlaxoSmithKline (I)
Stock and Other Ownership Interests - BerGenBio; GlaxoSmithKline (I)
Travel, Accommodations, Expenses - BerGenBio; GlaxoSmithKline (I)
 
David E. Gerber
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - BeiGene; Catalyst Pharmaceuticals; Janssen Oncology; Mirati Therapeutics; Regeneron; Samsung Bioepis; Sanofi
Research Funding - AstraZeneca (Inst); BerGenBio (Inst); Karyopharm Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending: “Prediction and Treatment of Immunotherapeutic Toxicity” (provisional, application number 62/461,455) (Inst); Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books.
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb